Nucleic Acid Based Drugs (NABDs) constitute a class of promising and powerful therapeutic new agents with limited side effects,
potentially useable against a wide range of diseases, including cancer. Among them, the short interfering RNAs (siRNAs), represent
very effective molecules. Despite their in vitro efficacy, the major drawback that limits siRNAs usage consists in a difficult delivery
due to their very low stability in physiological fluids, and to their limited membrane-permeability through physiological barriers. On the
other hand, the liposomes (lipid bilayers closed in vesicles of various sizes) represent interesting drug delivery systems (DDSs) which can
be tailored in order to get the best performance in terms of load, vesicle size and transfection yield. In this work, the current state of study
in these two fields, and the connections between them, are briefly summarized.